AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 12220769
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (0.625 mg conjugated equine estrogens alone or combined with 100 mg micronized progesterone)
Trial: 10629707
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy of the breast alone or zones of regional metastasizing (57 patients) with or without adjuvant chemotherapy or hormone therapy (tamoxifen)
Trial: 8552892
Drug: Drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug therapy for polymyositis
Trial: 1674014
Drug: Melatonin 5
RxNorm normalized name: melatonin 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melatonin 5 mg daily for 4 weeks
Trial: 18437013
Drug: Thoracoscopic procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Thoracoscopic procedure and pleurodesis with dextrose solution (group B)
Trial: 18437013
Drug: Thoracoscopic procedure
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Thoracoscopic procedure and pleurodesis with talc-dextrose mixed solution (group C)
Trial: 16482238
Drug: 7-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 7 days)
Trial: 16482238
Drug: 10-day triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day triple therapy (esomeprazole 20 mg, clarithromycin 500 mg, amoxycillin 1 g for 10 days)
Trial: 16482238
Drug: 10-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-day sequential regimen (esomeprazole 20 mg + amoxycillin 1 g for 5 days, followed by esomeprazole 20 mg, clarithromycin 500 mg, tinidazole 500 mg for 5 days)
Trial: 16482238
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 10-day sequential regimen vs 7-day triple therapy
Trial: 16482238
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 10-day sequential regimen vs 10-day triple therapy
Trial: 16482238
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of 7-day triple therapy vs 10-day triple therapy
Trial: 6823861
Drug: Labetalol (intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (intravenous administration)
Trial: 6823861
Drug: Labetalol (prolonged
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (prolonged oral therapy)
Trial: 25051056
Drug: Combination pill
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination pill (losartan 50 mg/hydrochlorothiazide 12.5 mg)
Trial: 23696676
Drug: Two pills
RxNorm normalized name: Two-Dyne Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two pills (angiotensin II receptor blocker and thiazide diuretic)
Trial: 19828203
Drug: Selective Serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective Serotonin Reuptake Inhibitor (SSRI) Treatment
Trial: 18154823
Drug: Methylprednisolone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (1 g)
Trial: 18154823
Drug: Triiodothyronine (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triiodothyronine (0.8 microg/kg bolus and 0.113 microg/kg/h infusion)
Trial: 9165973
Drug: Ondansetron 0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron 0.15 mg.kg‐1
Trial: 1547191
Drug: Probucol 1
RxNorm normalized name: Probucol
DrugBank: Probucol (DB01599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Probucol 1 g/day (4 tablets)
Trial: 1547191
Drug: Probucol 250
RxNorm normalized name: probucol 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol 250 mg/day (1 tablet)
Trial: 4059587
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg nalmefene
Trial: 30594227
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of Tranexamic acid (TXA) by intravenous injection immediately after the umbilical cord is cut or clamped
Trial: 18678826
Drug: 1,800 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1,800 mg/d EPA-DHA for 26 weeks
Trial: 18678826
Drug: 400 mg/d
RxNorm normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg/d EPA-DHA for 26 weeks
Trial: 15672985
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 100 mg, 200 mg, 100 mg, and 200 mg administered at 21:45, 23:45, 01:45, and 03:45
Trial: 12799091
Drug: Losartan 2
RxNorm normalized name: LOSARTAN 25MG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan 2 x 50 mg/d
Trial: 2662830
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of 300 mg of pentoxifylline (15 mL ampoules) administered over three hours twice daily.
Trial: 2662830
Drug: Placebo: 15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo: 15 mL of a 0.9% NaCl solution in 250 mL of 5% laevulose, administered over three hours twice daily.
Trial: 4581347
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg single dose)
Trial: 4581347
Drug: Propranolol (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (30 mg three times a day for one month)
Trial: 30745260
Drug: Adjunctive cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) for 2 months
Trial: 30745260
Drug: Adjunctive cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjunctive cervical non-invasive vagus nerve stimulation (nVNS) and sham stimulation
Trial: 23604570
Drug: Infliximab therapy
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Infliximab therapy at 5 mg/kg initially given at 0, 2, 6 weeks, then at 8-week intervals.
Trial: 23604570
Drug: C-reactive protein
RxNorm normalized name: C-reactive protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: C-reactive protein (CRP) >0.5 mg/dL.
Trial: 23107346
Drug: L-theanine +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine + placebo
Trial: 20131184
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 20 ml of bone marrow cells (BMC) after successful primary PCI
Trial: 20131184
Drug: Bare metal
RxNorm normalized name: menthone 1,2-glycerol ketal, (-)-
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bare metal stenting of the infarct-related artery (IRA) without BMC administration
Trial: 20131184
Drug: Intracoronary administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary administration of 20 ml of BMC
Trial: 10908007
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment offered by the programs at the eight participating sites
Trial: 9461944
Drug: 12.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg/kg ketamine
Trial: 9461944
Drug: 0.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 ml/kg of standard oral premedication (SOP)
Trial: 14621723
Drug: Monoclonal immunoglobulins
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoclonal immunoglobulins (mIg) identified by agarose gel electrophoresis and immunofixation
Trial: 2864892
Drug: Propranolol (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (11 mg)
Trial: 2864892
Drug: Hexamethonium (910
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hexamethonium (910 mg)
Trial: 2864892
Drug: Indomethacin (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (75 mg)
Trial: 30621047
Drug: Sanghuang⁻Danshen (SD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sanghuang⁻Danshen (SD) bioactives at 900 mg/day for 4 weeks
Trial: 22791244
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation (dispersible tablet)
Trial: 22791244
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation (branded capsule)
Trial: 20112368
Drug: Org 37663
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 37663 (4 mg/day)
Trial: 20112368
Drug: Org 37663
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 37663 (15 mg/day)
Trial: 20112368
Drug: Org 37663
RxNorm normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Org 37663 (50 mg/week)
Trial: 18173153
Drug: TCM treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCM treatment for dissolving phlegm and dispelling stasis (DP‐DS)
Trial: 11896446
Drug: Vero-IL-2 (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vero-IL-2 (both doses)
Trial: 9019380
Drug: 0.1 ml
RxNorm normalized name: ethanol 0.1 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1 ml Healon injected
Trial: 9019380
Drug: 0.2 ml
RxNorm normalized name: isopropyl alcohol 0.2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 ml Healon injected
Trial: 29900874
Drug: Dabigatran 110
RxNorm normalized name: dabigatran 110 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dabigatran 110 mg orally twice daily
Trial: 22004689
Drug: Zolpidem 10
RxNorm normalized name: zolpidem 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zolpidem 10 mg nightly for 12 months
Trial: 22738796
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine-based acupuncture
Trial: 20647199
Drug: Rituximab (375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rituximab (375 mg/m² per week for 4 weeks)
Trial: 20647199
Drug: Cyclophosphamide (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (2 mg/kg per day)
Trial: 17209171
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D dose > or = 250 microg/d (10,000 IU vitamin D3)
Trial: 7546499
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg enalapril/HCTZ (group II)
Trial: 7546499
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg enalapril/HCTZ (group III)
Trial: 2187213
Drug: Lorazepam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lorazepam (mean daily dose of 7 mg)
Trial: 2187213
Drug: Alprazolam (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam (mean daily dose of 3 mg)
Trial: 213186
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG treatment in addition to conventional therapy (surgery, radiotherapy or no treatment)
Trial: 213186
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG treatment with a full course of radiotherapy
Trial: 213186
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG treatment in patients with squamous carcinoma
Trial: 213186
Drug: Intradermal BCG
RxNorm normalized name: Tice BCG Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intradermal BCG treatment in patients with oat cell carcinoma
Trial: 31338688
Drug: SAGE-217 (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 (0.25 to 66 mg single dose)
Trial: 31338688
Drug: SAGE-217 (15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-217 (15, 30, or 35 mg once daily for 7 days)
Trial: 22687548
Drug: Cognitive remediation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive remediation condition including the Posit Science Brain Fitness auditory training program with weekly Neuropsychological and Educational Approach to Remediation (NEAR) 'bridging groups'
Trial: 22687548
Drug: Computer games
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Computer games and weekly healthy lifestyles groups (control condition)
Trial: 11851739
Drug: Botulinum toxin
RxNorm normalized name: Botulinum toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum toxin type A (BTX‐A) injections (up to 4.0 U BOTOX/kg/muscle, 16 U/kg/body weight every 6 months) plus SWASH brace
Trial: 11851739
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (BTX‐A/SWASH)
Trial: 9611669
Drug: Olanzapine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (10 +/- 2.5 mg)
Trial: 9611669
Drug: Olanzapine (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15 +/- 2.5 mg)
Trial: 9611669
Drug: Haloperidol (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (10-20 mg)
Trial: 29735019
Drug: EPA+DHA therapy
RxNorm normalized name: eicosapentaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EPA+DHA therapy (2.5 g/d)
Trial: 22656676
Drug: Hyperbaric ropivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric ropivacaine (11.25mg) + 2mL dextrose (5mg.mL(‐1))
Trial: 18729814
Drug: Carnosine (beta‐alanyl‐L‐histidine)
RxNorm normalized name: histidinal, L-
DrugBank: Carnosine (DB11695)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine (beta‐alanyl‐L‐histidine) as a food additive
Trial: 12414399
Drug: HOTL (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HOTL (daily wear)
Trial: 12414399
Drug: Control lens
RxNorm normalized name: lens scale pollen extract
DrugBank: Atriplex lentiformis pollen (DB10760)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control lens (daily wear)
Trial: 12414399
Drug: Both lenses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both lenses (daily wear)
Trial: 10359479
Drug: ipsapirone 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ipsapirone 0.3 mg/kg
Trial: 1782977
Drug: Buccal nitroglycerin
RxNorm normalized name: nitroglycerin Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal nitroglycerin every 4 hours
Trial: 1782977
Drug: Intravenous nitroglycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous nitroglycerin for 24 hours
Trial: 23011771
Drug: Tiotropium 18
RxNorm normalized name: TIOTROPIUM 18MCG CAP,INHL,6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg once-daily
Trial: 15134695
Drug: Glutamate (1
RxNorm normalized name: Glutamate (13-N)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutamate (1 M) injection into the MAR or right SP
Trial: 15134695
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isotonic saline injection into the MAR or SP
Trial: 11157009
Drug: FEC 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 50 (fluorouracil 500 mg/m2, epirubicin 50 mg/m2, cyclophosphamide 500 mg/m2)
Trial: 11157009
Drug: FEC 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FEC 100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, cyclophosphamide 500 mg/m2)
Trial: 2522008
Drug: Amlodipine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amlodipine (2.5 to 10 mg qd, mean 9 mg/d)
Trial: 28416247
Drug: Adaptive cardiac
RxNorm normalized name: Leonurus cardiaca extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adaptive cardiac resynchronization therapy (aCRT)
Trial: 21507028
Drug: DNK333 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNK333 25 mg b.d.
Trial: 21507028
Drug: DNK333 100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNK333 100 mg b.d.
Trial: 21507028
Drug: DNK333 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DNK333 25 mg b.d. (Trial 2)
Trial: 17021083
Drug: High-dose alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alpha2b interferon (6 million units/day) plus ribavirin (600 to 800 mg/day)
Trial: 17021083
Drug: Ribavirin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribavirin (600 to 800 mg/day)
Trial: 17021083
Drug: High-dose alpha2b
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose alpha2b interferon plus ribavirin
Trial: 10981565
Drug: Intravenous acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous acyclovir (10 mg/kg three times daily for 9 days) + prednisolone (60 mg per day with progressive reduction for 21 days)
Trial: 10981565
Drug: Epidural analgesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural analgesia (6-12 ml bupivacaine (0.25%) every 6-8 or 12 h) + methylprednisolone (40 mg every 3-4 days by epidural catheter for 7 to 21 days)
Trial: 9049576
Drug: Ibuprofen (7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (7.5 mg/kg per dose)
Trial: 9049576
Drug: Aspirin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (10 mg/kg/dose)
Trial: 9049576
Drug: Paracetamol (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (10 mg/kg per dose)
Trial: 8325065
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (400 mg for 2 weeks, followed by 600 mg for 2 weeks)
Trial: 15094031
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment + soma
Trial: 15094031
Drug: standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment + relaxation training
Trial: 11765290
Drug: Placebo, 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 5 mg, 10 mg, 15 mg (various doses)
Trial: 9290370
Drug: DACE group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DACE group (drainage, air injection, cryotherapy, and explant)
Trial: 9290370
Drug: CDAE group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CDAE group (cryotherapy, drainage, air injection, and explant)
Trial: 3521524
Drug: Doxepin hydrochloride
RxNorm normalized name: Doxepin Hydrochloride
DrugBank: Doxepin (DB01142)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxepin hydrochloride (mean maximal dose: 105 mg)
Trial: 3521524
Drug: Placebo (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (mean maximal dose: 128 mg)
Trial: 28566124
Drug: Topical melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical melatonin 12.5%
Trial: 28566124
Drug: Topical melatonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical melatonin 0.5% and 2.5%
Trial: 28566124
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and no treatment
Trial: 26230471
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of 5 mmol/L magnesium sulfate (MgSO4) solution for 14 days
Trial: 22357799
Drug: Therapist-led exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapist-led exercise therapy group (C1, n = 16)
Trial: 22357799
Drug: Non-therapist-led exercise
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-therapist-led exercise therapy group (C2, n = 16)
Trial: 9495978
Drug: Aspirin taken
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin taken preventively before adverse reactions of alpha-IFN
Trial: 9495978
Drug: Traditional routines
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional routines of aspirin administration
Trial: 28477289
Drug: Atomoxetine (1.2–1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (1.2–1.8 mg/kg/day) for 1 year, followed by randomization to atomoxetine for 6 months (n=81)
Trial: 28477289
Drug: Atomoxetine (80–100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atomoxetine (80–100 mg/day) for 6 months, followed by randomization to atomoxetine for 6 months (n=266)
Trial: 24807650
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of insurance intervention and capitation budget with pay-for-performance
Trial: 9193431
Drug: Ser447-Stop allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ser447-Stop allele carriers using beta-blockers
Trial: 9193431
Drug: Ser447-Stop allele
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ser447-Stop allele carriers not using beta-blockers
Trial: 1604251
Drug: High-dose methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose methylprednisolone (1000 mg)
Trial: 1604251
Drug: Low-dose methylprednisolone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose methylprednisolone (375 mg)